What Are the Side Effects of Taking Mounjaro?

Which side effects do most people actually notice?

In the SURMOUNT-1 trial, published in the New England Journal of Medicine, the overwhelming majority of reported adverse events were gastrointestinal. Nausea was the standout, followed by diarrhoea, vomiting and constipation. Indigestion, reflux, burping and a feeling of fullness that arrives faster than expected also feature regularly. Fatigue, headache and dizziness appear in a smaller proportion of users, and mild reactions at the injection site (redness, itching, a small lump) are occasional rather than routine.

The timing matters. Symptoms tend to cluster around two windows: the very start of treatment, and the days immediately after a dose increase. Between those peaks, most people find the picture settles considerably. Eating smaller portions, avoiding high-fat meals and staying well hydrated are practical habits that can take the edge off, though any specific dietary advice for your situation is worth discussing with your prescriber.

A quick habit that takes under a minute: before your next dose, check whether any new symptom started within 24–48 hours of the previous injection. If there's a consistent pattern, note it and flag it at your next clinical review. That kind of observation is more useful than a vague sense that something feels off. If you want a thorough breakdown before your next review, our page covering what the side effects of Mounjaro actually are sets out the full picture, and the NHS tirzepatide medicines page lists side effects and their frequencies and is worth bookmarking for reference.

Are there side effects that need urgent medical attention?

Yes, and it is worth being clear about which ones. Pancreatitis is the most clinically significant. In January 2026 the MHRA issued a Drug Safety Update specifically calling out acute pancreatitis as an infrequent but serious known risk with GLP-1 and dual-agonist medicines including tirzepatide. The symptom pattern to recognise: severe stomach pain that starts in the upper abdomen, persists rather than coming and going, and may radiate through to the back, sometimes with vomiting, sometimes without. That combination means calling 111 or going to A&E, not waiting to see how it develops.

Gallbladder problems, including gallstones and cholecystitis, are also listed in the safety profile. Upper-right abdominal pain, fever or jaundice are the signs. Separately, a small number of people experience allergic reactions (swelling of the face, lips or throat, difficulty breathing, or a rapid rash) which require immediate emergency help. Our dedicated page on pancreatitis and Mounjaro covers that risk in fuller detail, and a broader look at the risk profile sits on our Mounjaro risks page.

If anything worries you between reviews, our aftercare team is available seven days a week. You can also contact us directly.

How do side effects compare at different stages of treatment?

Mounjaro's licensed dosing starts at 2.5 mg as a tolerability step, the job of that first pen is to let your body adjust, not to deliver peak therapeutic effect. Side effects reported at 2.5 mg and 5 mg are typically milder than those reported at higher maintenance doses. As titration progresses, GI symptoms can resurface briefly with each step, then ease again. This pattern is why the prescribing schedule is gradual and why your prescriber may pause a dose increase if your body needs longer to adapt.

Long-term effects are a reasonable question. The SURMOUNT programme tracked participants over 72 weeks, and the picture that emerged was of a GI-heavy early phase that progressively quietened for most people. There are open questions about very long-term use, and that is one reason Mounjaro carries the Black Triangle designation, the MHRA continues to collect post-market data. You can read more about the long-term side effect evidence on a dedicated page, and if you are considering stopping treatment, the side effects of coming off Mounjaro are covered separately.

How does the clinical review at nume help manage side effects?

Because Mounjaro is a prescription-only medicine, a GPhC-registered Independent Prescriber reviews your consultation before any treatment is issued, and before every repeat. That means a clinician sees your health picture, your current medications and any relevant history each time, not just at the start. Side effects that interact with other conditions or medicines can be picked up before they become a problem.

People who are already on treatment elsewhere and considering transferring are asked to provide evidence of their current dose and any reactions, so the review is genuinely informed. Prescribers also discuss contraception, since tirzepatide can affect how oral contraceptives are absorbed during the first four weeks of treatment and after each dose step, a non-oral method is advised during those windows. For a full picture of how Mounjaro is assessed and dispensed, the Mounjaro overview page is the place to start, or you can explore all weight-loss treatment options to see how it fits alongside other approaches. If you are ready to have your suitability assessed, start your free consultation and our prescribers will go through everything, including what to expect from side effects, as part of that review.

Suspected side effects from any medicine, including Mounjaro, can be reported directly to the MHRA through the Yellow Card scheme, patients as well as healthcare professionals can submit reports, and doing so helps regulators build a more complete picture of how these medicines perform in the real world.